Anti-S1 Total Ab
Anti-NC Total Ab
detection of total antibodies against Spike RBD S1 protein
or Nucleocapsid (NC) protein of SARS-CoV-2
Anti-S1 Total Ab
Anti-NC Total Ab
detection of total antibodies against Spike RBD S1 protein
or Nucleocapsid (NC) protein of SARS-CoV-2
Serological tests for quantitative and qualitative detection of total antibodies against Spike RBD S1 protein or Nucleocapsid (NC) protein of SARS-CoV-2
by measuring both S1 and NC antibodies.
Time to results about 10 minutes.
with full traceability.
BENEFITS OF THE KITS:
- The quick solution for evaluating immunity status of patients
- Ideal solution for screening of community and population
- Applicable on most common clinical chemistry analyzers
- High performance, ready-to-use reagents, long shelf life and onboard stability
- Avoid interference due to Biotin and HAMA
- Better precision and repeatability than rapid card tests
- Very good correlation with PCR results
- Environmental sustainable product from ISO 14001:2015 certified company
THE IDEAL SOLUTION FOR
Comparison to alternative immunological method:
A total of 479 (105 positive and 374 negative) patients samples have been tested with the COVID-19 anti-S1 Total Ab and the COVID-19 anti-NC Total Ab kits and compared to the results of an automated commercial available method for detection of total antibodies to SARS-CoV-2.
| Clinical concordance |
COVID-19 Anti-S1 Total Ab |
COVID-19 Anti-S1 Total Ab |
| Area Under ROC curve (AUC) |
98.1% (95% CI: 96.8%-99.3%) |
95.8% (95% CI: 93.8%-97.9%) |
Relevant hints from the simultaneous processing of the sample with the two assays:
| COVID-19 Anti-S1 Total Ab | COVID-19 Anti-NC Total Ab | Type of antibodies | Exposure to the virus |
| + | + | Presence of – Neutralizing antibodies – Non-neutralizing antibodies |
Possible positivity due to past/present infection |
| + | – | Prevalence of – Neutralizing antibodies |
Possible positivity due to vaccination* |
| – | + | Prevalence of – Non-neutralizing antibodies |
Possible positivity due to past/present infection** |
| – | – | Absence of antibodies (or not detectable) | Possible absence of contact with the virus |
* If absence of Anti-NC antibodies is confirmed
** If presence of Anti-NC antibodies is confirmed after retesting
COVID-19 Anti-S1 Total Ab
Serological tests for quantitative and qualitative detection of total antibodies against Spike RBD S1 protein of SARS-CoV-2.
The information you need to order our
COVID-19 Anti-S1 Total Ab.
| Product |
|---|
| COVID-19 Anti-S1 Total Ab |
| Description |
| Immunoturbidimetric test for the quantitative and qualitative detection of human total antibodies against Spike RBD S1 protein of SARS-CoV-2 in human serum |
| Kit size |
| 200 tests |
| Reference |
| 1158701 |
| Target | Spike RBD S1 (S1) viral protein of the SARS-CoV-2 |
| Quality control | COVID-19 Total Ab Controls REF 1158703 (sold separately) |
| Sample | Human serum |
| Platforms | SENTiFIT® 270 Analyzer |
| Time to first result | About 10 minutes |
| Throughput | Up to 270 tests/h |
| Reagent on board stability | 28 days |
| Calibration stability | 14 days |
| Specificity | Cross reactivity has been evaluated in 90 samples* IgG positive to several viruses and in 60 samples* IgG positive to CMV. Specificity vs. other virus: 100% Specificity vs. CMV: 100% |
*All samples were obtained before Decembre 2019
COVID-19 Anti-NC Total Ab
Serological tests for quantitative and qualitative detection of total antibodies against Nucleocapsid (NC) protein of SARS-CoV-2.
The information you need to order our
COVID-19 Anti-NC Total Ab.
| Product |
|---|
| COVID-19 Anti-NC Total Ab |
| Description |
| Immunoturbidimetric test for the quantitative and qualitative detection of human total antibodies against Nucleocapsid protein of SARS-CoV-2 in human serum |
| Kit size |
| 200 tests |
| Reference |
| 1158702 |
| Target | Nucleocapsid (NC) viral protein of the SARS-CoV-2 |
| Quality control | COVID-19 Total Ab Controls REF 1158703 (sold separately) |
| Sample | Human serum |
| Platforms | SENTiFIT® 270 Analyzer |
| Time to first result | About 10 minutes |
| Throughput | Up to 270 tests/h |
| Reagent on board stability | 28 days |
| Calibration stability | 14 days |
| Specificity | Cross reactivity has been evaluated in 90 samples* IgG positive to several viruses and in 60 samples* IgG positive to CMV. Specificity vs. other virus: 99% Specificity vs. CMV: 100% |
*All samples were obtained before Decembre 2019
Product available for sale in EU and other selected Countries, please contact export@sentinel.it for info. Not for sale in the USA and Canada.
User-ID and password required. Please, register in the login page and enter in the laboratory section in order to download the SDS. Contact our Customer Service, if you need more information.
Discover our customized lyophilization service and find out how we can help in order to accelerate the launch of your products.
